Latest Conference Coverage

Enhertu achieved statistically significant and clinically meaningful improvements in progression-free survival compared with standard-of-care chemotherapy among patients with HR-positive, HER2-low metastatic breast cancer.

Results from new analysis show RYBREVANT plus lazertinib consistently and significantly improved progression-free survival compared to osimertinib.

Results showed non-inferior efficacy and pharmacokinetics for subcutaneous amivantamab combined with lazertinib compared to intravenous administration.

Results of the Phase III CheckMate -77T, CheckMate -816, and CheckMate -9LA trials show the potential of Opdivo to improve survival among patients with early and advanced stages of lung cancer.

New solution, CARA AI, will aid in the exploration of real-world data and leverage workflows such as imaging and cohort generation.

ICON plc CEO Steve Cutler discussed how strategic partnerships are driving advancements in clinical trials.

In an interview with ACT editor Andy Studna at SCOPE, Corrigan discusses what YPrime is doing to address challenges in clinical trials and results from the company's recently released eCOA report.

In an interview with ACT editor Andy Studna at SCOPE, Deyle, VP & GM, Clinical Research, Flatiron Health discusses real-world evidence in clinical trials.

In an interview with ACT editor Andy Studna at SCOPE, Young, Chief Science Officer, CluePoints discusses where the industry is currently adopting RBQM and the level of comfort that comes with it.

In an interview with ACT editor Andy Studna at SCOPE, Morahan, senior director, clinical data analytics, IQVIA Technologies discusses how AI can advance trial execution and what stakeholders should be keeping top of mind when choosing technology vendors.

Breakout session at SCOPE Summit 2024 discusses the potential use of artificial intelligence to improve clinical trial strategy generation.

Interactive panel at SCOPE discussed the potential of utilizing artificial intelligence in clinical trials.

Final results from inspIRE study demonstrate 80% freedom from atrial arrhythmia recurrence at 12 months; early results from admIRE study suggest similar outcomes.

Howell shares important insights from the most recent J.P. Morgan Healthcare Conference and addresses where the clinical trials industry currently is with innovation.

Trial shows Keytruda improved overall survival by 38% compared with placebo in in patients with renal cell carcinoma at intermediate-high or high risk of recurrence after nephrectomy or nephrectomy and resection of metastatic lesions.

In an interview with ACT editor, Andy Studna, Lieberman, Executive Director, Conferences (CHI) & Co-Founder, VP, Community and Business Development (ClinEco) discusses the Summit for Clinical Ops Executives (SCOPE) conferences in Europe and the US.

Satri-cel (satricabtagene autoleucel) showed a promising safety and efficacy profile in patients with gastric or gastroesophageal cancer and pancreatic cancer.

Applied Clinical Trials sat down on-site with many KOLs at some of industry's largest gatherings in 2023 including SCOPE, DIA, and DPHARM.

Interactive panel discussed the evolving area of data transfer and the usage of EHR-to-EDC.

Industry leaders gathered to address the current landscape of data collection in clinical trials.

Breakout session challenges current creation methods.

In an interview at SCOPE Europe 2023 with Applied Clinical Trials Editor, Andy Studna, Tony Mikulaschek, VP, eCOA, IQVIA Technologies addresses what stakeholders should be thinking of in the data collection space moving forward.

In an interview at SCOPE Europe 2023 with Applied Clinical Trials Editor, Andy Studna, Tony Mikulaschek, VP, eCOA, IQVIA Technologies discusses how regulatory bodies are currently viewing the data collection space.

In an interview at SCOPE Europe 2023 with Applied Clinical Trials Editor, Andy Studna, Tony Mikulaschek, VP, eCOA, IQVIA Technologies discusses how eCOAs are being applied to clinical trials.

Amy Cramer, steering committee board co-chair, HL7 FHIR Accelerator Vulcan, gives an overview of Vulcan at the 2023 DPHARM conference in Boston, MA.

Amy Cramer, steering committee board co-chair, HL7 FHIR Accelerator Vulcan, shares what she is currently seeing in the data space of clinical trials at the 2023 DPHARM conference in Boston, MA.

How can industry bring its latest technologies together?

Session discusses next steps to advancing evidence generation systems.